Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma - Two case reports

Neurologia Medico-Chirurgica

Volumn 45, Issue 12, 2005, Pages 650-652

  Makino, Keishi ^a   Kochi, Masato ^a   Nakamura, Hideo ^a   Kuroda, Jun Ichiro ^a   Honda, Yoshiteru ^b   Ushio, Yukitaka ^a   Kuratsu, Jun Ichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colestimide; Malignant lymphoma; Methotrexate

Indexed keywords

ANION EXCHANGE RESIN; COLESTILAN; FOLINIC ACID; METHOTREXATE;

ACCELERATION; ADULT; ANOREXIA; ARTICLE; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTOXICATION; DRUG MEGADOSE; ENTEROHEPATIC CIRCULATION; HUMAN; IN VITRO STUDY; LYMPHOMA; MALE; NAUSEA;

ADMINISTRATION, ORAL; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; EPICHLOROHYDRIN; HUMANS; IMIDAZOLES; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; RESINS, SYNTHETIC;

EID: 29544441985     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.45.650     Document Type: Article

References (15)

1. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144-3150, 2000
2. Baird GM, Dossetor JF: Methotrexate enteropathy. Lancet 1: 164, 1981
3. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289: 770-773, 1973
4. Calvert AH, Bondy PK, Harrap KR: Some observations on the human pharmacology of methotrexate. Cancer Treat Rep 61: 1647-1656, 1977
5. Carey JB Jr: The altered distribution of the bile acid pool in obstructive jaundice and its correction including relief of pruritus with a bile acid sequestering resin. J Clin Invest 40: 1028, 1961
6. Chabner BA, Johns DG, Bertino JR: Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 239: 395-397, 1972
7. Chabner BA, Young RC: Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804-1811, 1973
8. Erttmann R, Landbeck G: Effect of oral cholestyramine on the elimination of high-dose methotrexate. J Cancer Res Clin Oncol 110: 48-50, 1985
9. Gadgil SD, Damle SR, Advani SH, Vaidya AB: Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treat Rep 66: 1169-1171, 1982
10. Honda Y, Nakano M: Studies on adsorption characteristics of bile acids and methotrexate to a new type of anion-exchange resin, colestimide. Chem Pharm Bull (Tokyo) 48: 978-981, 2000
11. Huffman DH, Wan SH, Azarnoff DL, Hogstraten B: Pharmacokinetics of methotrexate. Clin Pharmacol Ther 14: 572-579, 1973
12. Leme PR, Creaven PJ, Allen LM, Berman M: Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 59: 811-817, 1975
13. Lui CY, Lee MG, Chiou WL: Clearance studies of methotrexate in dogs after multiple-rate infusion. Cancer Res 45: 1545-1548, 1985
14. Shinozaki T, Watanabe H, Tomidokoro R, Yamamoto K, Horiuchi R, Takagishi K: Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate. Med Pediatr Oncol 34: 226-228, 2000
15. Stoller RG, Jacobs SA, Drake JC, Lutz RJ, Chabner BA: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemother Rep 6: 19-24, 1975